Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.
Hearps AC, Vootukuru N, Ebrahimnezhaddarzi S, Harney BL, Boo I, Nguyen L, Pavlyshyn D, Dietze PM, Drummer HE, Thompson AJ, Jaworowski A, Hellard ME, Sacks-Davis R, Doyle JS
Hepatitis C Injecting Drug Use
Approaches and reporting of alcohol and other drug testing for injured patients in hospital-based studies: A systematic review.
Lau G, Ang JY, Kim N, Gabbe BJ, Mitra B, Dietze PM, Reeder S, Beck B.
Alcohol and Other Drugs
Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines: Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia.
O'Keefe D, Jacka D, Douglass C, Gunn J, Stoove M, Crawford S, Bryant M, Higgs P, Dietze P, Hellard M
Hepatitis C Injecting Drug Use
The National Naloxone Reference Group: A collective voice on take-home naloxone policy and practice in Australia.
Dietze P, Stewart A, Hill P, Draper B, Curtis M, Kirwan A, National Naloxone Reference Group
Alcohol and Other Drugs Injecting Drug Use
The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia.
Roxburgh A, Livingston M, Dietze P, Nielsen S, Cogger S, Bartlett M, Day C, Latimer J, Jauncey M, Clark N
COVID-19
Socioeconomic consequences of the COVID-19 pandemic for people who use drugs
S. Walker, P. Dietze, P. Higgs, B. Ward, C. Treloar, M. Stoové, K. Rathnayake, J. Doyle, M. Hellard, L. Maher